Your browser doesn't support javascript.
loading
Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma.
Yuan, Shumin; Fu, Qiang; Zhao, Lingdi; Fu, Xiaomin; Li, Tiepeng; Han, Lu; Qin, Peng; Ren, Yingkun; Huo, Mingke; Li, Zhimeng; Lu, Chaomin; Yuan, Long; Gao, Quanli; Wang, Zibing.
Afiliação
  • Yuan S; Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Fu Q; Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Zhao L; Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Fu X; Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Li T; Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Han L; Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Qin P; Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Ren Y; Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Huo M; Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Li Z; Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Lu C; Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Yuan L; Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Gao Q; Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Wang Z; Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Oncologist ; 27(6): e463-e470, 2022 06 08.
Article em En | MEDLINE | ID: mdl-35348754
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Piridinas / Melanoma / Recidiva Local de Neoplasia Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Piridinas / Melanoma / Recidiva Local de Neoplasia Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article